Expanding the portfolio of anaplastic lymphoma kinase inhibitors for anaplastic lymphoma kinase-rearranged lung cancers Journal Article


Authors: Santini, F. C.; Salhab, R. M.; Sharma, S.; Drilon, A.
Article Title: Expanding the portfolio of anaplastic lymphoma kinase inhibitors for anaplastic lymphoma kinase-rearranged lung cancers
Keywords: cancer survival; treatment response; overall survival; constipation; fatigue; neutropenia; diarrhea; drug efficacy; hypertension; side effect; unspecified side effect; edema; progression free survival; gastrointestinal symptom; lung disease; nausea; vomiting; lung cancer; editorial; dyspnea; pneumonia; oncogene; drug fatality; gene rearrangement; brain metastasis; peripheral edema; interstitial lung disease; creatine kinase; aminotransferase; pemetrexed; visual disorder; triacylglycerol lipase; non small cell lung cancer; anaplastic lymphoma kinase; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); hypertransaminasemia; crizotinib; alk gene; human; ceritinib; alectinib; anaplastic lymphoma kinase inhibitor; brigatinib; lorlatinib
Journal Title: Translational Cancer Research
Volume: 6
Issue: Suppl. 9
ISSN: 2218-676X
Publisher: Pioneer Bioscience Publishing Company  
Date Published: 2017-12-01
Start Page: S1418
End Page: S1421
Language: English
DOI: 10.21037/tcr.2017.10.42
PROVIDER: scopus
DOI/URL:
Notes: Editorial -- Export Date: 2 January 2018 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Alexander Edward Drilon
    388 Drilon
  2. Shorabh Sharma
    1 Sharma